<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02696226</url>
  </required_header>
  <id_info>
    <org_study_id>16-084</org_study_id>
    <nct_id>NCT02696226</nct_id>
  </id_info>
  <brief_title>Frequency of Reduced Leaflet Motion After Surgical Aortic Valve Replacement and Transcatheter Aortic Valve Replacement.</brief_title>
  <official_title>A Pilot Study of Subclinical Leaflet Thrombosis in Bioprosthetic Aortic Valves: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized pilot study in patients undergoing Sugical Aortic Valve
      Replacement (SAVR) and Transcatheter Aortic Valve Replacement (TAVR) to estimate the
      incidence of reduced leaflet motion and assess the impact of perioperative anticoagulation on
      the incidence of reduced leaflet motion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a pilot prospective randomized controlled trial.The study will enroll 50 adult
      patients scheduled to undergo SAVR and 50 adult patients scheduled to undergo TAVR. Subjects
      who satisfy Inclusion/Exclusion Criteria will be approached for informed consent. Those who
      give informed consent will be enrolled. After induction of anesthesia, a computer program
      will be used to randomize patients to one of the 2 treatment groups.

        1. SAVR patients will get either Warfarin or aspirin

        2. TAVR patients will get either Warfarin or aspirin.

      Patients will be seen at 4-6 weeks postoperatively for Transthoracic ECHO (TTE), 4
      dimensional (4D), Multidetector computed tomography (MDCT) scan and review of medical
      history. Phone follow up at 6,9 and 12 months post-operatively.

      Data from this pilot study will enable us to determine the feasibility of a larger randomized
      controlled clinical trial to investigate the phenomenon of reduced leaflet motion/subclinical
      valve thrombosis and, possibly, its clinical importance
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor enrollment
  </why_stopped>
  <start_date type="Actual">February 2016</start_date>
  <completion_date type="Actual">July 28, 2017</completion_date>
  <primary_completion_date type="Actual">July 28, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Leaflet Motion</measure>
    <time_frame>4-6 weeks post procedure</time_frame>
    <description>Frequency of reduced leaflet motion related to perioperative anticoagulation with warfarin as measured by 4DMCT data. (&lt;50% reduction in motion), moderately reduced (50 to 70% reduction), severely reduced (&gt;70% reduction), or immobile (lack of motion of at least one valve leaflet).</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Aortic Valve Disorder</condition>
  <arm_group>
    <arm_group_label>SAVR Warfarin Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Warfarin arm-(target INR of 2-3)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAVR Warfarin and Clopidogrel Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Warfarin (target INR of 2-3) and Clopidogrel (75mg/day) arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAVR Aspirin Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aspirin arm (81mg/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAVR Aspirin and Clopidogrel Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aspirin (81mg/day) and Clopidogrel (75mg/day) arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAVR Warfarin</intervention_name>
    <description>Warfarin treatment for 12 weeks with a target INR of 2-3 Warfarin treatment to begin on postoperative day 1-3 according to the patient's clinical status When warfarin treatment is discontinued, patients will be treated according to standard of care (aspirin 81 mg/day) indefinitely</description>
    <arm_group_label>SAVR Warfarin Arm</arm_group_label>
    <other_name>Coumadiin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAVR Aspirin</intervention_name>
    <description>Aspirin (81 mg/day) to begin within 1-3 postoperative days according to the patient's clinical status and continue indefinitely per standard of care.</description>
    <arm_group_label>SAVR Aspirin Arm</arm_group_label>
    <other_name>Aspirin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAVR Warfarin and clopidogrel</intervention_name>
    <description>Begin Warfarin and clopidogrel (75 mg/day) treatment within 1-3 days postop for 12 weeks with a target INR of 2-3 When warfarin is discontinued, begin aspirin (81 mg/day) and continue aspirin/clopidogrel for 12 weeks At 24 weeks, study treatment will end and patients will be treated according to standard of care (aspirin 81 mg/day) indefinitely</description>
    <arm_group_label>TAVR Warfarin and Clopidogrel Arm</arm_group_label>
    <other_name>Coumadin</other_name>
    <other_name>Plavix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAVR Aspirin and clopidogrel</intervention_name>
    <description>Aspirin (81 mg/day) and clopidogrel (75 mg/day) in periprocedural period and continue for 24 weeks At 24 weeks, study treatment will end and patients will be treated according to standard of care (aspirin 81 mg/day) indefinitely</description>
    <arm_group_label>TAVR Aspirin and Clopidogrel Arm</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Scheduled for SAVR or TAVR

          -  Age &gt; 18 years

          -  Able and willing to give informed consent

          -  Able and willing to return for follow up

        Exclusion Criteria:

          -  Contraindications to warfarin, Plavix or aspirin

          -  Pre-existing medical indication for warfarin, Plavix or aspirin

          -  History of previous cardiac surgery

          -  History of previous coronary artery stenting

          -  Requirement for concomitant coronary artery bypass grafting or mitral valve surgery or
             surgical treatment of an ascending aortic aneurysm

          -  Contraindications to contrast-enhanced MDCT including anaphylactic iodine allergy,
             uncontrolled atrial fibrillation, renal dysfunction (GFR &lt; 60 ml/min).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Douglas Johnston, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2016</study_first_submitted>
  <study_first_submitted_qc>February 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2016</study_first_posted>
  <results_first_submitted>September 11, 2017</results_first_submitted>
  <results_first_submitted_qc>October 11, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">November 8, 2017</results_first_posted>
  <last_update_submitted>October 11, 2017</last_update_submitted>
  <last_update_submitted_qc>October 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Cleveland Clinic</investigator_affiliation>
    <investigator_full_name>Douglas Johnston</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>SAVR Warfarin Arm</title>
          <description>Warfarin arm-(target INR of 2-3)
SAVR Warfarin: Warfarin treatment for 12 weeks with a target INR of 2-3 Warfarin treatment to begin on postoperative day 1-3 according to the patient’s clinical status When warfarin treatment is discontinued, patients will be treated according to standard of care (aspirin 81 mg/day) indefinitely</description>
        </group>
        <group group_id="P2">
          <title>TAVR Warfarin and Clopidogrel Arm</title>
          <description>Warfarin (target INR of 2-3) and Clopidogrel (75mg/day) arm
TAVR Warfarin and clopidogrel: Begin Warfarin and clopidogrel (75 mg/day) treatment within 1-3 days postop for 12 weeks with a target INR of 2-3 When warfarin is discontinued, begin aspirin (81 mg/day) and continue aspirin/clopidogrel for 12 weeks At 24 weeks, study treatment will end and patients will be treated according to standard of care (aspirin 81 mg/day) indefinitely</description>
        </group>
        <group group_id="P3">
          <title>SAVR Aspirin Arm</title>
          <description>Aspirin arm (81mg/day)
SAVR Aspirin: Aspirin (81 mg/day) to begin within 1-3 postoperative days according to the patient’s clinical status and continue indefinitely per standard of care.</description>
        </group>
        <group group_id="P4">
          <title>TAVR Aspirin and Clopidogrel Arm</title>
          <description>Aspirin (81mg/day) and Clopidogrel (75mg/day) arm
TAVR Aspirin and clopidogrel: Aspirin (81 mg/day) and clopidogrel (75 mg/day) in periprocedural period and continue for 24 weeks At 24 weeks, study treatment will end and patients will be treated according to standard of care (aspirin 81 mg/day) indefinitely</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study terminated - lack of enrollment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Study terminated - lack of enrollment</population>
      <group_list>
        <group group_id="B1">
          <title>SAVR Warfarin Arm</title>
          <description>Warfarin arm-(target INR of 2-3)
SAVR Warfarin: Warfarin treatment for 12 weeks with a target INR of 2-3 Warfarin treatment to begin on postoperative day 1-3 according to the patient’s clinical status When warfarin treatment is discontinued, patients will be treated according to standard of care (aspirin 81 mg/day) indefinitely</description>
        </group>
        <group group_id="B2">
          <title>TAVR Warfarin and Clopidogrel Arm</title>
          <description>Warfarin (target INR of 2-3) and Clopidogrel (75mg/day) arm
TAVR Warfarin and clopidogrel: Begin Warfarin and clopidogrel (75 mg/day) treatment within 1-3 days postop for 12 weeks with a target INR of 2-3 When warfarin is discontinued, begin aspirin (81 mg/day) and continue aspirin/clopidogrel for 12 weeks At 24 weeks, study treatment will end and patients will be treated according to standard of care (aspirin 81 mg/day) indefinitely</description>
        </group>
        <group group_id="B3">
          <title>SAVR Aspirin Arm</title>
          <description>Aspirin arm (81mg/day)
SAVR Aspirin: Aspirin (81 mg/day) to begin within 1-3 postoperative days according to the patient’s clinical status and continue indefinitely per standard of care.</description>
        </group>
        <group group_id="B4">
          <title>TAVR Aspirin and Clopidogrel Arm</title>
          <description>Aspirin (81mg/day) and Clopidogrel (75mg/day) arm
TAVR Aspirin and clopidogrel: Aspirin (81 mg/day) and clopidogrel (75 mg/day) in periprocedural period and continue for 24 weeks At 24 weeks, study treatment will end and patients will be treated according to standard of care (aspirin 81 mg/day) indefinitely</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="2"/>
            <count group_id="B4" value="0"/>
            <count group_id="B5" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Study was terminated - low number of participants did not allow for data analysis</description>
          <population>Study terminated - lack of enrollment</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="2"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>Data was not analyzed due to low enrollment</description>
          <population>Data was not analyzed due to low enrollment - Study terminated</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="2"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Leaflet Motion</title>
        <description>Frequency of reduced leaflet motion related to perioperative anticoagulation with warfarin as measured by 4DMCT data. (&lt;50% reduction in motion), moderately reduced (50 to 70% reduction), severely reduced (&gt;70% reduction), or immobile (lack of motion of at least one valve leaflet).</description>
        <time_frame>4-6 weeks post procedure</time_frame>
        <population>Study terminated</population>
        <group_list>
          <group group_id="O1">
            <title>SAVR Warfarin Arm</title>
            <description>Warfarin arm-(target INR of 2-3)
SAVR Warfarin: Warfarin treatment for 12 weeks with a target INR of 2-3 Warfarin treatment to begin on postoperative day 1-3 according to the patient’s clinical status When warfarin treatment is discontinued, patients will be treated according to standard of care (aspirin 81 mg/day) indefinitely</description>
          </group>
          <group group_id="O2">
            <title>TAVR Warfarin and Clopidogrel Arm</title>
            <description>Warfarin (target INR of 2-3) and Clopidogrel (75mg/day) arm
TAVR Warfarin and clopidogrel: Begin Warfarin and clopidogrel (75 mg/day) treatment within 1-3 days postop for 12 weeks with a target INR of 2-3 When warfarin is discontinued, begin aspirin (81 mg/day) and continue aspirin/clopidogrel for 12 weeks At 24 weeks, study treatment will end and patients will be treated according to standard of care (aspirin 81 mg/day) indefinitely</description>
          </group>
          <group group_id="O3">
            <title>SAVR Aspirin Arm</title>
            <description>Aspirin arm (81mg/day)
SAVR Aspirin: Aspirin (81 mg/day) to begin within 1-3 postoperative days according to the patient’s clinical status and continue indefinitely per standard of care.</description>
          </group>
          <group group_id="O4">
            <title>TAVR Aspirin and Clopidogrel Arm</title>
            <description>Aspirin (81mg/day) and Clopidogrel (75mg/day) arm
TAVR Aspirin and clopidogrel: Aspirin (81 mg/day) and clopidogrel (75 mg/day) in periprocedural period and continue for 24 weeks At 24 weeks, study treatment will end and patients will be treated according to standard of care (aspirin 81 mg/day) indefinitely</description>
          </group>
        </group_list>
        <measure>
          <title>Leaflet Motion</title>
          <description>Frequency of reduced leaflet motion related to perioperative anticoagulation with warfarin as measured by 4DMCT data. (&lt;50% reduction in motion), moderately reduced (50 to 70% reduction), severely reduced (&gt;70% reduction), or immobile (lack of motion of at least one valve leaflet).</description>
          <population>Study terminated</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>SAVR Warfarin Arm</title>
          <description>Warfarin arm-(target INR of 2-3)
SAVR Warfarin: Warfarin treatment for 12 weeks with a target INR of 2-3 Warfarin treatment to begin on postoperative day 1-3 according to the patient’s clinical status When warfarin treatment is discontinued, patients will be treated according to standard of care (aspirin 81 mg/day) indefinitely</description>
        </group>
        <group group_id="E2">
          <title>TAVR Warfarin and Clopidogrel Arm</title>
          <description>Warfarin (target INR of 2-3) and Clopidogrel (75mg/day) arm
TAVR Warfarin and clopidogrel: Begin Warfarin and clopidogrel (75 mg/day) treatment within 1-3 days postop for 12 weeks with a target INR of 2-3 When warfarin is discontinued, begin aspirin (81 mg/day) and continue aspirin/clopidogrel for 12 weeks At 24 weeks, study treatment will end and patients will be treated according to standard of care (aspirin 81 mg/day) indefinitely</description>
        </group>
        <group group_id="E3">
          <title>SAVR Aspirin Arm</title>
          <description>Aspirin arm (81mg/day)
SAVR Aspirin: Aspirin (81 mg/day) to begin within 1-3 postoperative days according to the patient’s clinical status and continue indefinitely per standard of care.</description>
        </group>
        <group group_id="E4">
          <title>TAVR Aspirin and Clopidogrel Arm</title>
          <description>Aspirin (81mg/day) and Clopidogrel (75mg/day) arm
TAVR Aspirin and clopidogrel: Aspirin (81 mg/day) and clopidogrel (75 mg/day) in periprocedural period and continue for 24 weeks At 24 weeks, study treatment will end and patients will be treated according to standard of care (aspirin 81 mg/day) indefinitely</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Douglas Johnston</name_or_title>
      <organization>Cleveland Clinic</organization>
      <phone>216-444-5613</phone>
      <email>JOHNSTD3@ccf.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

